Showing posts with label Drugs. Show all posts
Showing posts with label Drugs. Show all posts

Friday, August 25, 2017

Limited Modern Drugs Determine Neuropathy In S African Kids


Today's post from aidsmap.com (see link below) highlights a problem that just doesn't seem to go away and is based on the lack of financial resources. The fact is that many HIV+ children in Africa are still being given older HIV drugs to control the virus; the result being consistently high numbers of kids suffering terribly from neuropathy brought about from the drugs themselves. The older drugs are cheaper; the pharmaceutical companies refuse to lower the prices of modern drugs sufficiently and the incidence of neuropathy therefore remains stable but never reduces. It's scandalous in today's world that children have to suffer from nerve damage symptoms purely because of arguments over the costs of drugs suppressing the HIV virus they carry. Drug companies must bear a large percentage of the blame!

Peripheral neuropathy in South African children highlights limited ARV choices
Carole Leach-Lemens Published: 23 July 2012

Jump to
Look out for peripheral nerve damage; "talk to the child", advises researcher
Reference
Further information

Look out for peripheral nerve damage; "talk to the child", advises researcher

Peripheral neuropathy was identified in one-in-four children on HIV treatment in rural Mopani District, one of the poorest and least well-resourced areas in South Africa, Dr Remco Peters reported today at the 19th International AIDS Conference (AIDS 2012) in Washington, DC.

The findings underline the importance of improving paediatric antiretroviral formulations suitable for use in sub-Saharan Africa.

In this cross-sectional study of 182 children, aged from 5 to 15, 86% were receiving an antiretroviral (ART) regimen that included d4T (stavudine, Zerit).

Among HIV-infected adults, peripheral neuropathy is common and well recognised. It affects between 30 and 60% of people with HIV and may be related to HIV infection and/or the drugs used to treat HIV. Few studies have been able to distinguish between peripheral neuropathy as a result of HIV itself and neuropathy as a side-effect of ART. Other contributing factors include vitamin and mineral deficiencies and autoimmune effects.

Peripheral nerves are responsible for sensation-pain, pressure, heat sensation (sensory nerves) movement (motor nerves) and automatic bodily functions such as breathing, heartbeat, sweating and emptying of the stomach (autonomic nerves). Damage to these nerves is called neuropathy.

In most people with HIV, nerve damage usually starts in the hands or feet (hence the term 'peripheral' neuropathy), affecting both sides of the body and involving multiple nerves. It can range from mild numbness or pain to debilitating pain. Other symptoms include increased sensitivity to touch, diminished reflexes and weakness. It can severely affect quality of life.

Stavudine (d4T) and didanosine (ddI, Videx, Videx EC) are two of the anti-HIV drugs known as dideoxynucleoside reverse transcriptase inhibitors or ‘d-drugs’, which can cause peripheral neuropathy.

The World Health Organization (WHO), concerned about the side effects of d4T (principally abnormal body fat loss, or lipoatrophy, and peripheral neuropathy in adults) has urged national treatment programmes – wherever affordable – to drop d4T and move to tenofovir- (Viread) or AZT-based treatment regimens in adults.

The findings of the study presented today are likely to reinforce calls for access to paediatric formulations of abacavir (Ziagen) in settings where d4T is the only current alternative. Abacavir is already available for paediatric use in southern Africa, and is recommended by the World Health Organization as a component of first-line paediatric treatment, but remains substantially more expensive than stavudine.

A powder version of tenofovir suitable for use in children aged two to five years is licensed for use in the United States, but safety studies have not been carried out in children in sub-Saharan Africa to evaluate any potential risk of kidney toxicity or decreased bone mineral density. The South African HIV Clinicians Society has suggested that tenofovir should be used with caution in young children until further safety data are available.

In June of this year, WHO issued guidance on the best use of tenofovir in adolescents and children over two years of age The recommended dose is 8 mg/kg body weight (up to a maximum of 300 mg), administered once daily using either an oral powder formulation or low-strength tablets. Caution is needed nonetheless since tenofovir in combination with ddI increases the risk of ddI-related toxicities, including peripheral neuropathy.

Peripheral neuropathy is diagnosed based on symptoms and is more difficult to diagnose in children. Few tools exist for clinical screening for peripheral neuropathy in children. Children may find it difficult to describe their symptoms.

Few data exist on the extent, symptoms or causes of peripheral neuropathy among HIV-positive children in sub-Saharan Africa, where d4T is in common use. Among the estimated 2.3 million HIV-positive children, between 2008 and 2009, approximately 90% were on an ART regimen containing d4T.

The researchers chose to use neuropathy symptom score (NSS) and neuropathy disability score (NDS) to screen for peripheral neuropathy in this cohort of children.

NSS, a subjective assessment tool, includes a series of questions about location and severity of pain and pain relief (for example, does sitting help?) in the feet and legs. Each response is given a score of 0, 1 or 2. Total scores of 3, 5 and 7 indicate mild, moderate and severe neuropathy, respectively.

The NDS, an objective assessment tool, looks at ankle reflex (0, 1 or 2), vibration perception (0 or 1), pin-prick perception (0 or 1) and temperature perception (0 or 1) and scored. A reflex hammer, cotton swabs, a toothpick and cold water are all that is needed to carry out the test.

An NSS score equal to or above 3 or an NDS score equal to or above 2 was used as a definitive diagnosis of peripheral neuropathy. Dr Remco noted these were conservative cut-off points.

In total, 96% (174/182) of this cohort of children, all collecting ART from nurse-managed treatment programmes, completed screening for peripheral neuropathy. This included a questionnaire, physical exam, NSS and NDS scores.

The median age was 9.2 years with median time on ART of two years (2 months to 6.4 years).

Forty-nine children (27%) reported symptoms related to neuropathy, while 25 children (14%) met the NDS criteria. Overall, 43 children (25%) were identified as having peripheral neuropathy. Examples of children's descriptions of symptoms included:
“My feet are burning, I must take off my shoes in class otherwise I can’t concentrate.”
“I can’t sleep at night because of the tingling in my feet; I’m tired during the day.”

Dr Remco noted that, while the cause of peripheral neuropathy was not addressed in depth, being on ART for a longer period of time (p=0.06) was a major contributor.

Dr Remco concluded that, in this region, peripheral neuropathy among children is common and often goes undiagnosed. Simple and easy to use, the NSS and NDS are valuable tools for assessing peripheral neuropathy in a resource-poor and skills-limited setting.

The most important lesson learned is “quite simply, to talk to the child”, he added. In these settings, “We [healthcare workers] do not talk to the children, we will talk to the mother or caregiver about the child but never directly to the child.” 


Reference

van Ramshorst R et al. Clinical screening shows high prevalence of peripheral neuropathy in children taking antiretroviral therapy in rural South Africa. 19th International Conference on AIDS, abstract MOAB0205, Washington, DC, July 2012.

http://www.aidsmap.com/Peripheral-neuropathy-in-South-African-children-highlights-limited-ARV-choices/page/2448363/

Monday, August 21, 2017

New Drugs To Be Targeted At Pain Receptors Deep In The Nerve Cell


Today's post from sciencedaily.com (see link below) may at first sight seem a little difficult to understand but basically, when the body experiences pain, there are pain receptors on the surface of nerve cells that identify it and transmit the information further and let you feel that pain. If the pain is extreme, sometimes these pain receptors retreat to the nucleus of the cell, as if it's 'safer' there. Pain relieving drugs are designed to block the pain signals in the receptors at the surface of the cell but if the receptors have migrated to the nucleus then the drugs don't have any effect. This knowledge enables researchers to design pain-relieving drugs that can penetrate the nerve cell to the nucleus and thus block the signals from reaching the receptors. They can then 'safely' return to the surface of the cell. At least that's the theory and although it may seem like double-dutch to most of us, sometimes it's interesting to know in which direction the scientists are going.
 


Location may be key to effectively controlling pain
Date:February 3, 2016 Source:McGill University
 
In real estate, location is key. It now seems the same concept holds true when it comes to stopping pain. New research published in Nature Communications indicates that the location of receptors that transmit pain signals is important in how big or small a pain signal will be -- and therefore how effectively drugs can block those signals.

Blocking pain receptors in the nucleus of spinal nerve cells could more effectively control pain than interfering with the same type of receptors located on cell surfaces. The scientists also found that when spinal nerve cells encounter a painful stimulus, some of the receptors will migrate from the cell surface into the nucleus.

A team of researchers led by McGill University's Director of Anesthesia Research Terence Coderre and Karen O'Malley at Washington University in St. Louis, found that rats treated with investigational drugs to block the activity of the receptors in the nucleus soon began behaving in ways that led them to believe the animals had gotten relief from neuropathic pain. According to Prof. Coderre, "drugs that penetrate the spinal nerve cells to block receptors at the nucleus were effective at relieving pain, while those that don't penetrate the nerve cells were not. Rats with nerve injuries had less spontaneous pain and less pain hypersensitivity after blocking receptors at the nucleus, while the pain sensitivity of normal rats was not affected."

Location is key
Scientists have been studying glutamate receptors in the pain pathway for decades. What's new, Coderre explained, is that these most recent experiments -- in cell cultures and rats -- demonstrate that the location of the receptor in the cell has a major effect on the cell's ability to transmit pain signals.

The researchers focused mainly on nerve cells in the spinal cord, an important area for transmitting pain signals coming from all parts of the body.

"We'll now focus our research at determining what events cause the glutamate receptors to migrate to the nucleus, and how to produce drugs that more specifically block glutamate receptors only at the nucleus," added Coderre.

Story Source:

The above post is reprinted from materials provided by McGill University. The original item was written by Cynthia Lee. Note: Materials may be edited for content and length.

Journal Reference:
Kathleen Vincent, Virginia M. Cornea, Yuh-Jiin I. Jong, André Laferrière, Naresh Kumar, Aiste Mickeviciute, Jollee S. T. Fung, Pouya Bandegi, Alfredo Ribeiro-da-Silva, Karen L. O’Malley, Terence J. Coderre. Intracellular mGluR5 plays a critical role in neuropathic pain. Nature Communications, 2016; 7: 10604 DOI: 10.1038/NCOMMS10604


http://www.sciencedaily.com/releases/2016/02/160203111018.htm

Wednesday, August 16, 2017

Neuropathy Caused By Prescription Drugs Vid


Today's video post from beatingneuropathy.tv (see link below) sees Dr John Hayes talk about a subject that's all over the internet at the moment and that's neuropathy caused by some of the drugs used to treat other conditions (statins and certain types of antibiotics for instance). It is essential to ask your doctor if the drugs he or she prescribes, are likely to cause neuropathy and if so, ask for alternatives. If you're still not happy, Google the name of the drug and neuropathy and see if there are potential problems.



Episode 36 – Drug-Induced Neuropathy
Wednesday, December 4th, 2013
Posted by John Hayes Jr

Drug induced neuropathy is now more common than ever. In this video, Dr. Hayes discusses the most common drugs that are associated with the eventual development of neuropathy. Watch carefully, listen and learn. Be especially careful if you take or have taken in the past statins, antihypertensives, and modern classes of antibiotics.



http://beatingneuropathy.tv/2013/12/episode-36-drug-induced-neuropathy/

Sunday, August 6, 2017

Important Information About Anti Seizure Drugs And HIV Meds


Today's post from dailyrx.com (see link below) looks at something which maybe alarming for HIV patients with neuropathy, who are currently prescribed anti-seizure or anti-convulsion drugs (for instance, Gabapentine, Lamotrigine and others). The American Academy of Neurology issued guidelines in January, 2012, that urge caution for doctors prescribing seizure drugs for patients on anti-retrovirals because the they can directly affect the working of the HIV meds. It is important that you consult your doctor/HIV specialist if you fall into this category (as many people with neuropathy and HIV do). Your doctor may not be aware of these latest developments and may need to adjust the dosage of your meds, or even change them.


HIV Patients Choose Seizure Drugs Carefully
By:Lindsay Patterson Reviewed by: Joseph V. Madia, MD  January 8, 2012

Seizure drugs for HIV AIDS patients have new AAN guidelines

(dailyRx News) A new guideline from the American Academy of Neurology urges caution for doctors prescribing seizure drugs for patients also taking anti-retroviral drugs for HIV.

Seizures are common among people infected with HIV, and 55 percent of people taking anti-retroviral drugs (ARVs) are also taking anti-epileptic drugs (AEDs) to prevent seizures.

But certain types of these drugs, when taken together, can have dangerous interactions or cause anti-HIV medications to fail.


"Ask your doctor if your medications follow the new guideline."

The AAN guideline is the first formal guideline for treating patients who are taking bothARVs and seizure drugs.

The paper supporting the new guideline reports that worldwide use of both ARVs and seizure drugs is substantial. HIV patients may experience seizures resulting from other conditions that took advantage of their weakened immune system.

Seizure drugs are also used to treat other conditions, such as bipolar disorder and neuropathic pain.

According to the guideline, there are several negative outcomes that can come from different drug combinations. Some interactions can cause either drug to become more toxic to the body.

Seizure drugs that work to reduce ARV levels in the blood, like phenytoin, phenobarbital and carbamazepine, can make the patient's anti-HIV treatment less effective, leading to the disease progressing towards AIDS, and resistance to ARVs.

These dangerous interactions are of special concern for patients in developing countries. In Sub-Saharan Africa, for example, HIV is widespread and choice of drugs is limited.

Lead guideline author Dr. Gretchen L. Birbeck of Michigan State University advised that patients know exactly what drugs they're taking, and give that information to all of their healthcare providers to avoid dangerous interactions in drugs prescribed by different doctors.

The guideline also recommended dosages for each drug. The full text of the guideline follows:

“Patients receiving phenytoin may require a lopinavir/ritonavir dosage increase of 50% to maintain unchanged serum concentrations (Level C). Patients receiving valproic acid may require a zidovudine dosage reduction to maintain unchanged serum zidovudineconcentra- tions (Level C). Coadministration of valproic acid and efavirenz may not require efavirenz dosage adjustment (Level C).

Patients receiving ritonavir/atazanavir may require a lamotrigine dosage increase of 50% to maintain unchanged lamotrigine serum concentrations (Level C). Coadmin- istration ofraltegravir/atazanavir and lamotrigine may not require lamotrigine dosage adjustment (Level C). Coadministration of raltegravir and midazolam may not require midazolamdosage ad- justment (Level C).

Patients may be counseled that it is unclear whether dosage adjustment is necessary when other AEDs and ARVs are combined (Level U). It may be important to avoid enzyme-inducing AEDs in people on ARV regimens that include protease inhibitors ornonnucleo- side reverse transcriptase inhibitors, as pharmacokinetic interactions may result in virologic fail- ure, which has clinical implications for disease progression and development of ARV resistance.

If such regimens are required for seizure control, patients may be monitored through pharmacokinetic assessments to ensure efficacy of the ARV regimen (Level C).”


http://www.dailyrx.com/seizure-drugs-hiv-aids-patients-have-new-aan-guidelines

The Role Of The FDA In Testing New Drugs


Today's post from healthychildren.org (see link below) is especially interesting to neuropathy patients who are not only confronted by a long list of drugs intended for other medical purposes but are also tempted by claims elsewhere, of miraculous cures and treatments involving strangely-named medications. Most people have heard of the FDA (The U.S. Food and Drug Administration) and are aware that that body approves and disapproves new medications as they come on the market. For people outside the USA, their own health authorities very often follow the guidelines of the FDA when it comes to making drugs available in their own lands. It's useful then to know how the FDA works and how and why it comes to its conclusions. Remember, the FDA almost always errs on the side of caution, so you can be reasonably sure that if a drug is FDA approved, it's safe. There have been slip-ups in the past but these are generally swiftly rectified. Interesting article.


FDA’s Role in the Drug Approval Process

Last Updated4/2/2015 SourceAmerican Academy of Pediatrics and U.S. Food and Drug Administration (Copyright © 2015)
This article provides information about the FDA's drug approval process.


What Does it Mean For a Product to be "FDA-Approved?"

The U.S. Food and Drug Administration (FDA) examines, tests, and approves a wide range of items for medical use, including drugs, medical devices, food, cosmetics and many other health-related products. In the simplest terms, "FDA approval" means that the FDA has decided the benefits of the approved item outweigh its potential risks.

Before the FDA, companies could make claims about a product, without proof that it was safe or that it even worked. This made consumers extremely vulnerable. Now, new products must go through the FDA approval process before they are available to the public.


Why is the FDA Approval Process Important?

FDA approval is important, because it validates the need for research on how drugs work on children, not just adults. It also allows us the properly determine the appropriate dosage for children, determine the best route of administration, and test for any drug interactions.


How Does a Drug or Device Get FDA Approval?

In order to receive FDA approval for a drug or a medical device, the manufacturer must prove to the FDA that the item is "safe and effective." Although no drug or medical device is entirely risk-free, the research and testing must show that the benefits of the drug or device for a particular condition outweigh the risks to patients of using the item.
Here's a brief overview of the steps involved in a drug becoming FDA-approved:
Drug Developed: A company develops a new drug and seeks to have it approved by the FDA for sale in the United States.


Animal Testing: Before testing the drug on people, the company must test the new drug on animals to find out whether it has the potential to cause serious harm (i.e. toxicity).
IND Application: The company submits an Investigational New Drug (IND) application to the FDA based on the results from the initial animal testing. These results must include the drug's composition and manufacturing and the proposed plan for testing the drug on people.
Clinical Trials: After the FDA reviews and approves the IND application, clinical trials to test the drug on people can begin. There are 4 phases of clinical trials, starting with small-scale trials, followed by large-scale trials. After the clinical trials, the researchers then submit study reports to the FDA.
NDA Application: Once a drug developer provides evidence that the drug is safe and effective, the company can file a New Drug Application (NDA). The FDA reviews the application and makes a decision to approve or not approve the drug.
Drug Labeling: The FDA reviews the drug's labeling/packaging and makes sure appropriate information is communicated to health care professionals and consumers.
Facility Inspection: The FDA inspects the facilities where the drug will be manufactured.
Drug Approval: The FDA approves the NDA or issues a response letter.
Post-Marketing Monitoring: Once the FDA approves the drug, the company is required to submit periodic safety updates to the FDA. 


Do Over-the-Counter Drugs and Medical Devices Need FDA Approval?

Yes. Drugs sold over-the-counter (without a prescription) must be approved by the FDA. For instance, over-the-counter pain medications must be FDA-approved to treat pain.


What is Considered When Rescheduling A Drug?

The Controlled Substances Act (CSA), part of the Comprehensive Drug Abuse Prevention and Control Act of 1970, is the legal cornerstone of the government’s war against drug abuse. The U.S. Drug Enforcement Administration (DEA) has divided these substances into five categories, called “schedules,” based on each drug’s (1) potential for abuse, (2) safety, (3) addictive potential and (4) whether or not it has any legitimate medical applications.. Schedule I is reserved for drugs considered to have the highest potential for abuse and no current accepted medical use. Rescheduling marijuana, for example, would not make it legal but reclassifying the schedule could potentially increase research being done on the drug. Click here to learn more about the FDA's drug approval approcess and marijuana.

http://www.healthychildren.org/English/health-issues/conditions/treatments/Pages/FDAs-Role-in-the-Drug-Approval-Process.aspx

Tuesday, August 1, 2017

Acid Reflux Drugs And Neuropathy


Today's post from wellnessachiever.net (see link below) talks about the possible risks associated with acid reflux drugs that many people take to counter the effects of other medications on the stomach. Prilosec, Losec, prevacid, omeprazol etc can bring on neuropathic symptoms after long-term use. They create vitamin B12 deficiency (a well known cause of neuropathy) Many patients need to stay on these drugs for as long as their main medication is necessary but there are risks. Apart from this, acid reflux drugs can prevent absorption of supplements and vitamins thus wasting your money in that respect too. This article explains the whole process very well. Always worth talking over with your doctor.

Acid Reflux Drugs May Cause Dementia and Neuropathy 
by Dr. Brent Hunter December 11, 2013

Has your memory been slipping lately? Have you experienced unexplained pain, weakness, numbness or tingling in your arms of legs? Have you also been taking an acid reflux drug like Nexium, Prevacid or Prilosec for a couple years? If so, then you may be the latest victim of the pharmaceutical industry’s medical model of healthcare.

After that first paragraph, you may have expected to see an attorney’s phone number to call and join a class action lawsuit! Well, I am sure that it won’t be long before that actually happens. New research, published Monday in The Journal of the American Medical Association (JAMA), showed that certain acid reflux drugs are “significantly associated” with vitamin B12 deficiency. In turn, vitamin B12 deficiency causes serious health consequences including anemia, osteoporosis, depression, memory loss, dementia, neuropathy and cardiovascular disease. 

If you have acid reflux, you need to understand what is causing it. Find the cause and correct the cause. Simply popping pills to block the natural production of stomach acid has proven to only cause even more serious health conditions. Read on to learn how to restore your health without these dangerous drugs! 

Acid Reflux Drugs Linked to Vitamin B12 Deficiency


Acid reflux drugs, like Nexium, have long been known to cause some very serious side effects. Among them are problems such as anemia, heart problems, hypertension, osteoporosis and further digestive problems including irritable bowel syndrome (IBS). In fact, drugs used to treat acid reflux do not treat the condition itself but only the symptoms. They are not designed to correct the cause of the problem. As a result, the problem continues to worsen over the years. Drug treatment is continued and the drug side effects continue to worsen as well.

This new research(1) sheds further light on this problem. It showed that people taking certain acid reflux drugs are far more likely to suffer from vitamin B12 deficiency. The study implicated proton pump inhibitors (PPIs) – Nexium, Prevacid and Prilosec – and histamine 2 receptor antagonists (H2RAs) – Pepcid, Tagamet and Zantac. Proton pump inhibitors proved to be the worst.

Unfortunately, the study’s senior author, Dr. Douglas Corley, stated(2) that patient’s should not stop taking the drugs but should get their B12 levels checked. If your levels are deficient, then presumably, you should treat that as another symptom as well. All the while, the underlying causes are left unaddressed. Vitamin B12 deficiency cannot be corrected unless the cause of the deficiency is addressed. In this case, the cause may be your acid reflux pill.

Left uncorrected, this leads to fatigue, anemia, irritable bowel syndrome, increased risk of bone fracture, hypertension, dementia, depression and neuropathy. It is dangerous, costly, and simply ridiculous to continue treating symptoms of any condition rather than addressing the cause. Wouldn’t it be much better to find what is causing the acid reflux and correct the cause?
Why Do You Have Stomach Acid?

Stomach acid has been unjustly vilified as the cause of acid reflux and GERD. In a similar fashion, cholesterol was incorrectly pegged as the cause of deadly heart disease. Just as pharmaceutically lowering cholesterol increases the heart attack death rate, blocking stomach acid with drugs only makes the problem of reflux and GERD even worse!

You have acid in your stomach for a reason. The cells that line your stomach produce it. In fact, your stomach is specifically designed with a layer of cells that protect it from the otherwise damaging effects of the acid. This stomach acid is required by your body for:

proper digestion of food, especially carbohydrates

Absorption of nutrients (such as vitamin B12)

Killing harmful bacteria and limiting bacterial overgrowth

Without this acid in your stomach, you cannot properly digest carbohydrates or effectively absorb certain nutrients. Blocking this acid production also allows for overgrowth of bacteria and opens the door for H. pylori infections. Simply having the stomach acid is not the problem. In fact, most people suffering from acid reflux actually have too little stomach acid rather than too much.


What Causes Acid Reflux and GERD?

The problem is when the acid leaks (refluxes) into the esophagus. Your esophagus does not have the protective lining that your stomach has. When stomach acid gets into the esophagus, the burning pain of acid reflux results.

Your body has a very strong valve – called the Lower Esophageal Sphincter (LES) – between the stomach and esophagus that is designed to prevent the reflux of acid. The cause of the acid reflux is a dysfunctioning LES muscle which allows the acid to reflux into the esophagus.

It is not a problem of having too much acid. Again, most cases of acid reflux actually occur with low levels of stomach acid. The acid is just in the wrong place. Lowering acid levels or blocking its production does not fix the problem with the LES. As a result, the acid reflux continues and you are prescribed acid blocking drugs for the rest of your life.

So, the real question is what is causing the dysfunction with the LES muscle and how can your correct this cause of acid reflux?

 
Correcting the Cause of Acid Reflux

Your Nerve System and Chiropractic Care. The LES is an autonomic muscle. That means that it is automatically controlled by your autonomic nervous system. Stress on the nerves that control this muscle can cause it to malfunction. Additionally, production and secretion of stomach acid is controlled by your nerve system. Ensuring proper nerve system function is the first step to healing acid reflux and GERD naturally. Chiropractic physicians are trained to find and correct nerve interference such as this. As a result, many people experience significant relief simply from including regular chiropractic care in their wellness lifestyle.

Eliminating Drug Effects. It is also important to consider other prescription drugs that you are taking that may be causing the problem. Common culprits include steroid drugs, NSAIDS (such as Advil and Aleve), and aspirin. These drugs are commonly prescribed for various pain syndromes. However, there are many natural, safe, and more effective methods for correcting these conditions as well.

Excessive Carbohydrates. Consuming excessive carbohydrates – especially simple carbs like sugars, breads, pastas, pastries, etc. – create an inflammatory environment in your body. This can prevent normal production of stomach acid and allow bacterial overgrowth. This leads to gas production and increased intra-abdominal pressure. As a result the LES muscle becomes inhibited and acid reflux occurs. Simply switching to a low carbohydrate, anti-inflammatory diet naturally corrects this cause of acid reflux.

Balancing Bacteria. Low stomach acid allows for bacterial overgrowth and disrupts the balance of healthy gut bacteria. Consuming foods rich in probiotics (healthy bacteria), such as raw fermented foods, restores this balance. Taking a probiotic supplement may be necessary as well. Restoring the normal, healthy bacteria in your gut helps to correct many digestive disorders, including acid reflux. 


Natural Remedies for Acid Reflux

Using these methods addresses the actual cause of acid reflux and GERD and allows your body to heal itself naturally. While you are healing, you may need to use some natural remedies as well to help with the symptoms. As mentioned earlier, the problem is most often a result of not enough stomach acid production in order to digest food, absorb nutrients and kill harmful bacteria.

Bitter herbs can be used to increase production of stomach acid. These include herbs such as barberry bark, caraway, dandelion, fennel, ginger, goldenseal root, peppermint, and wormwood. They are typically taken in very small doses and made in a tincture of water. Consult an well-trained herbalist for best results.

While you are reconditioning your body to produce the proper amount of stomach acid, you may benefit from natural digestive enzyme supplements as well. Without proper levels of stomach acid, the pH is too high to stimulate the release of these enzymes naturally. These supplements can help provide your body with the support it needs to break down carbohydrates and proteins more effectively.
As with all health conditions, dangerous drugs are not the only option. It may seem easy to simply pop a pill and ignore the problem. However, your body and your long-term health will ultimately suffer the consequences. You can live a radiant and vibrantly healthy life! Simple lifestyle changes make a huge difference in your vitality and they will help you heal acid reflux naturally!
Please share this information with your friends and family on Facebook and Twitter. Please also Subscribe to WellnessAchiever.net and receive free email updates. Simply scroll down and enter your information in the “Stay Informed!” box below. Here’s to your great health!

References for this Article:

(1) Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12 Deficiency http://jama.jamanetwork.com/article.aspx?articleid=1788456

(2) Stomach acid drugs may increase vitamin deficiency risk http://www.reuters.com/article/2013/12/10/us-stomach-acid-drugs-vitamin-d-idUSBRE9B914Y20131210?feedType=RSS&feedName=healthNews

http://wellnessachiever.net/acid-reflux-drugs-may-cause-dementia-neuropathy/

Thursday, July 20, 2017

MILD HYPERTENSION CAN BE TREATED WITHOUT DRUGS




For people with mild hyper-tension, encouraging lifestyle changes should be the first line of recommendations for physicians rather than putting them on drugs, suggest experts.
Lead researcher Stephen Martin and colleagues argue that the current strategy is failing patients and
wasting healthcare resources.
"Over-emphasis on drug treatment risks adverse effects such as increased risk of falls and misses opportunities to modify individual lifestyle choices," they noted.
They called for a re-examination of the threshold and urge clinicians to be cautious about treating low risk patients with blood pressure lowering drugs.
Up to 40 percent of adults worldwide have hyper-tension, over half of which is classified as mild.
Low risk indicates that an individual does not have existing cardio-vascular diseases, diabetes or kidney diseases.
Over the years, hyper-tension has been treated with drugs at progressively lower blood pressures.
"We urge clinicians to share the uncertainty surrounding drug treatment of mild hypertension with patients, measure blood pressure at home, improve accuracy of clinic measurements and encourage lifestyle changes," Martin concluded.
They were scheduled to discuss the findings at the 2014 Preventing Overdiagnosis Conference hosted by the Centre for Evidence-based Medicine at the University of Oxford.

Sunday, July 16, 2017

Acid Reflux Drugs Can Play Havoc With Your Nervous System


Today's post from naidw.org (see link below) looks once again at a subject that crops up quite frequently on the neuropathy message boards and that's the negative influence of commonly-used, acid-reflux drugs including:
Rabeprazole (Aciphex) Esomeprazole (Nexium) Lansoprazole  Prevacid)
Omeprazole (Prilosec, Zegerid) Pantoprazole (Protonix) exlansoprazole (Dexilant) on our nervous systems. It becomes especially relevant if you've been prescribed these drugs to protect your stomach from excessive acid production by other drugs, for other conditions (HIV combinations are a good example). It's surprising how many people are also prescribed these drugs and end up staying on them for years, long after the original need has passed. The consequences can be very serious indeed! Apart from the potential damage to your nervous system; if your stomach's natural acid production is suppressed, it means that certain drugs will never be allowed to work because the acid needed to break them down, is terminally suppressed by the acid-reflux medication. Reading this article will provide you with all the information you need and should help you decide if you need to have a serious discussion with your doctor or not. The less acid-reflux drugs, the better - certainly for your neuropathy problems.


Acid Reflux Drugs May Cause Dementia and Neuropathy
Thursday, 18 February 2016

Has your memory been slipping lately? Have you experienced unexplained pain, weakness, numbness or tingling in your arms of legs? Have you also been taking an acid reflux drug like Nexium, Prevacid or Prilosec for a couple years? If so, then you may be the latest victim of the pharmaceutical industry’s medical model of healthcare.

After that first paragraph, you may have expected to see an attorney’s phone number to call and join a class action lawsuit! Well, I am sure that it won’t be long before that actually happens. New research, published Monday in The Journal of the American Medical Association (JAMA), showed that certain acid reflux drugs are “significantly associated” with vitamin B12 deficiency. In turn, vitamin B12 deficiency causes serious health consequences including anemia, osteoporosis, depression, memory loss, dementia, neuropathy and cardiovascular disease.

If you have acid reflux, you need to understand what is causing it. Find the cause and correct the cause. Simply popping pills to block the natural production of stomach acid has proven to only cause even more serious health conditions. Read on to learn how to restore your health without these dangerous drugs!

Acid Reflux Drugs Linked to Vitamin B12 Deficiency


Acid reflux drugs, like Nexium, have long been known to cause some very serious side effects. Among them are problems such as anemia, heart problems, hypertension, osteoporosis and further digestive problems including irritable bowel syndrome (IBS). In fact, drugs used to treat acid reflux do not treat the condition itself but only the symptoms. They are not designed to correct the cause of the problem. As a result, the problem continues to worsen over the years. Drug treatment is continued and the drug side effects continue to worsen as well.

This new research(1) sheds further light on this problem. It showed that people taking certain acid reflux drugs are far more likely to suffer from vitamin B12 deficiency. The study implicated proton pump inhibitors (PPIs) – Nexium, Prevacid and Prilosec – and histamine 2 receptor antagonists (H2RAs) – Pepcid, Tagamet and Zantac. Proton pump inhibitors proved to be the worst.

Unfortunately, the study’s senior author, Dr. Douglas Corley, stated(2) that patient’s should not stop taking the drugs but should get their B12 levels checked. If your levels are deficient, then presumably, you should treat that as another symptom as well. All the while, the underlying causes are left unaddressed. Vitamin B12 deficiency cannot be corrected unless the cause of the deficiency is addressed. In this case, the cause may be your acid reflux pill.

Left uncorrected, this leads to fatigue, anemia, irritable bowel syndrome, increased risk of bone fracture, hypertension, dementia, depression and neuropathy. It is dangerous, costly, and simply ridiculous to continue treating symptoms of any condition rather than addressing the cause. Wouldn’t it be much better to find what is causing the acid reflux and correct the cause? 


Why Do You Have Stomach Acid?

Stomach acid has been unjustly vilified as the cause of acid reflux and GERD. In a similar fashion,cholesterol was incorrectly pegged as the cause of deadly heart disease. Just as pharmaceutically lowering cholesterol increases the heart attack death rate, blocking stomach acid with drugs only makes the problem of reflux and GERD even worse!

You have acid in your stomach for a reason. The cells that line your stomach produce it. In fact, your stomach is specifically designed with a layer of cells that protect it from the otherwise damaging effects of the acid. This stomach acid is required by your body for:


proper digestion of food, especially carbohydrates


Absorption of nutrients (such as vitamin B12)


Killing harmful bacteria and limiting bacterial overgrowth


Without this acid in your stomach, you cannot properly digest carbohydrates or effectively absorb certain nutrients. Blocking this acid production also allows for overgrowth of bacteria and opens the door for H. pylori infections. Simply having the stomach acid is not the problem. In fact, most people suffering from acid reflux actually have too little stomach acid rather than too much.
What Causes Acid Reflux and GERD?

The problem is when the acid leaks (refluxes) into the esophagus. Your esophagus does not have the protective lining that your stomach has. When stomach acid gets into the esophagus, the burning pain of acid reflux results.

Your body has a very strong valve – called the Lower Esophageal Sphincter (LES) – between the stomach and esophagus that is designed to prevent the reflux of acid. The cause of the acid reflux is adysfunctioning LES muscle which allows the acid to reflux into the esophagus.

It is not a problem of having too much acid. Again, most cases of acid reflux actually occur with low levels of stomach acid. The acid is just in the wrong place. Lowering acid levels or blocking its production does not fix the problem with the LES. As a result, the acid reflux continues and you are prescribed acid blocking drugs for the rest of your life.

So, the real question is what is causing the dysfunction with the LES muscle and how can your correct this cause of acid reflux?


Correcting the Cause of Acid Reflux

Your Nerve System and Chiropractic Care.
The LES is an autonomic muscle. That means that it is automatically controlled by your autonomic nervous system. Stress on the nerves that control this muscle can cause it to malfunction. Additionally, production and secretion of stomach acid is controlled by your nerve system. Ensuring proper nerve system function is the first step to healing acid reflux and GERD naturally. Chiropractic physicians are trained to find and correct nerve interference such as this. As a result, many people experience significant relief simply from including regular chiropractic care in their wellness lifestyle.


Eliminating Drug Effects. It is also important to consider other prescription drugs that you are taking that may be causing the problem. Common culprits include steroid drugs, NSAIDs (such as Advil and Aleve), and aspirin. These drugs are commonly prescribed for various pain syndromes. However, there are many natural, safe, and more effective methods for correcting these conditions as well.


Excessive Carbohydrates. Consuming excessive carbohydrates – especially simple carbs like sugars, breads, pastas, pastries, etc. – create an inflammatory environment in your body. This can prevent normal production of stomach acid and allow bacterial overgrowth. This leads to gas production and increased intra-abdominal pressure. As a result the LES muscle becomes inhibited and acid reflux occurs. Simply switching to a low carbohydrate, anti-inflammatory dietnaturally corrects this cause of acid reflux.

Balancing Bacteria. Low stomach acid allows for bacterial overgrowth and disrupts the balance of healthy gut bacteria. Consuming foods rich in probiotics (healthy bacteria), such as raw fermented foods, restores this balance. Taking a probiotic supplement may be necessary as well. Restoring the normal, healthy bacteria in your gut helps to correct many digestive disorders, including acid reflux.


Natural Remedies for Acid Reflux

Using these methods addresses the actual cause of acid reflux and GERD and allows your body to heal itself naturally. While you are healing, you may need to use some natural remedies as well to help with the symptoms. As mentioned earlier, the problem is most often a result of not enough stomach acid production in order to digest food, absorb nutrients and kill harmful bacteria.

Bitter herbs can be used to increase production of stomach acid. These include herbs such as barberry bark, caraway, dandelion, fennel, ginger, goldenseal root, peppermint, and wormwood. They are typically taken in very small doses and made in a tincture of water. Consult an well-trained herbalist for best results.

While you are reconditioning your body to produce the proper amount of stomach acid, you may benefit from natural digestive enzyme supplements as well. Without proper levels of stomach acid, the pH is too high to stimulate the release of these enzymes naturally. These supplements can help provide your body with the support it needs to break down carbohydrates and proteins more effectively.
As with all health conditions, dangerous drugs are not the only option. It may seem easy to simply pop a pill and ignore the problem. However, your body and your long-term health will ultimately suffer the consequences. You can live a radiant and vibrantly healthy life! Simple lifestyle changes make a huge difference in your vitality and they will help you heal acid reflux naturally!

References for this Article:


(1) Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12 Deficiencyhttp://jama.jamanetwork.com/article.aspx?articleid=1788456

(2) Stomach acid drugs may increase vitamin deficiency riskhttp://www.reuters.com/article/2013/12/10/us-stomach-acid-drugs-vitamin-d-idUSBRE9B914Y20131210?feedType=RSS&feedName=healthNews

https://naidw.org/blog/members-myblogs/acid-reflux-drugs-may-cause-dementia-and-neuropathy

Thursday, July 13, 2017

Conclusions About Effectiveness Of Neuropathy Drugs


Today's post from bodyinmind.org (see link below) takes a look at the drugs currently used to control neuropathic pain and comes to conclusions which most of us concluded years ago - the drugs are not particularly effective at all but maybe they're better than nothing! The author also questions drug trials and the reporting of such, hinting that there are often hidden agendas behind the publication of results and that trial study numbers can also be misleading. You may not learn much new here but it's always interesting to read honest, expert opinion, especially when it backs up our own previously held suspicions.
 


The effectiveness of drugs for neuropathic pain – what do we know?
July 17, 2015 by Neil O'Connell 

Neuropathic pain (NP) – that is pain arising from identifiable damage or disease affecting the somatosensory nervous system is common and frequently severe and life-changing. It is also notoriously difficult to treat effectively. Indeed we know that for many people with NP treatment is inadequate. The International Association for the Study of Pain (IASP) have a special interest group “NeuPSIG” focused explicitly on understanding the mechanisms, assessment, prevention and treatment of NP. They have just published an up to date systematic review on the effectiveness of pharmacotherapy in Lancet Neurology. Better still it has now been made available beautifully open access. You can download it for free here.

This is a comprehensive review, containing 229 trials of the full range of pharmacological agents using robust methods, to synthesize, summarise and make value judgements about the quality of the available evidence. So what are the take home messages?

Using a primary outcome of achieving at least 50% pain relief trial outcomes were described as “generally modest”. The number of patient needed to treat with the drug compared to a placebo for one more person to achieve this outcome ranged from a relatively rosy 3.6 (95% confidence interval 3 to 4.4) for tricyclic antidepressants such as amitryptiline, 4.3 (95%CI 3.4 to 5.80 for strong opioids to a less impressive 7.2 (95%CI 5.9 to 9.21) for gabapentin, and 7.7 (6.5 to 9.4) for pregabalin (often sold under the brand-name Lyrica). It’s interesting, at least to me, how much better the older more traditional agents seem to have fared compared on effectiveness to the more modern (and commonly more expensive) agents although the safety and tolerability of gabapentin seems superior.

The spectre of publication bias also raises its head. The reviewers carefully took a number of routes to try to unpick this notoriously difficult issue and estimate that there has been overall a 10% overstatement of treatment effects. Published studies reported larger effect sizes than did unpublished studies. This is not a problem restricted to the field of pain trials. It is a burning issue across the world of clinical trials. It is very important because if we fail to base our clinical recommendations on the totality of relevant evidence (because some data are hidden from us) we are in danger of mis-estimating the benefits and the harms and as a result patients are put at risk. If you think that is pretty important then there are ways that you can help. Check out the All-Trials campaign.

Overall what does this mean? Many drugs are effective but not as effective as we would wish them to be. No pharmacological agent really impresses and for any drug the most probable outcome is failure to produce 50% pain relief. There are various potential reasons for this. The first is that the drugs may only be moderately or marginally effective, another is that neuropathic pain includes quite a mixed bag and our ability to accurately diagnose and to target drugs to specific mechanisms in the clinic is currently fairly poor.

The NeuPSIG review team formulate a number of recommendations for revision of their clinical guideline for managing NP pain, balancing the benefits, harms, costs and strength of the evidence:
a strong recommendation for use and proposal as a first-line treatment in neuropathic pain for tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, pregabalin, and gabapentin;
a weak recommendation for use and proposal as a second line treatment for lidocaine patches, capsaicin high-concentration patches, and tramadol; and a weak recommendation for use and proposal as third line for strong opioids and botulinum toxin A. Topical agents and botulinum toxin A are recommended for peripheral neuropathic pain only.
 

Neil O’Connell

As well as writing for Body in Mind, Dr Neil O’Connell, (PhD, not MD) is a lecturer and researcher in the College of Health and Life Sciences (Department of Clinical Sciences) at Brunel University London, UK. He divides his time between research and training new physiotherapists and previously worked extensively as a musculoskeletal physiotherapist.

He also tweets! @NeilOConnell

Neil’s main research interests are chronic low back pain and chronic pain more broadly with a focus on evidence based practice. He has conducted numerous systematic reviews and is a member of the editorial board of the Cochrane Collaboration’s Pain Palliative and Supportive Care Group (PaPaS). He also makes a mean Yorkshire pudding despite being a child of Essex. Link to Neil’s published research here. Downloadable PDFs here.
References

Finnerup NB, Attal N, Haroutounian S et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol.

http://www.bodyinmind.org/drugs-neuropathic-pain/

Tuesday, July 4, 2017

Evidence Based Conclusions about Neuropathy Drugs


This very interesting article comes from Neurology Today (see link below) and looks at the effectiveness of certain drugs used to treat neuropathy, based on research and trials. The general conclusion is that Pregabalin fits the bill best but if you read the Editor of Neurology Today's own conclusions (below), it reflects not so much how wonderful Pregabalin is but the scattered and random nature of the studies and trials used to determine drug value. The fact is that there just haven't been enough studies of the various neuropathy treatments carried out; so that the one drug comes out better than the other because there is more available evidence concerning that particular drug and not because it necessarily compares better to all the others. Therefore Pregabalin becomes a Level A drug here because the research has been wider and better, than for other comparable drugs. This is not to say that Pregabalin isn't effective - for many people it clearly is but the comparisons with other drugs are just not sufficiently tested and evaluated. The only trustworthy conclusion to be drawn here is that once again, you shouldn't believe all you read in the papers!

(Don't be put off by the word 'Diabetic' in the title; the article applies to neuropathy in general.)

New Evidence-Based Guidelines for Painful Diabetic Neuropathy
Samson, Kurt: Neurology Today: 05 May 2011 - Volume 11 - Issue 9 - pp 1,4-5

ARTICLE IN BRIEF

The AAN, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation jointly released a guideline, suggesting the best available evidence supported use of pregabalin for treating painful diabetic neuropathy.

A new evidence-based guideline for treating painful diabetic neuropathy (PDN) supports the use of several therapeutic options, most significantly the use of the seizure drug pregabalin, which was approved by the FDA in 2007.

The results were presented April 11 as an expedited publication in Neurology, the April edition of the journal Muscle and Nerve from the American Association of Neuromuscular and Electrodiagnostic Medicine, as well as the April issue of PM&R, the American Academy of Physical Medicine and Rehabilitation's scientific journal.

About 16 percent of some 25 million people with diabetes in the United States suffer from PDN, yet it is often unreported and untreated, with an estimated two out of five patients not receiving any care, according to the report.

Lead author Vera Bril, MD, professor of neurology at Toronto General Hospital in Ontario, Canada, discussed with Neurology Today the findings and what they mean for patients and their physicians

HOW DID THE PANEL CATEGORIZE STUDY QUALITY?

First we did a literature search of all relevant studies between 1960 and August 2008, and 2,234 citations were identified. The study titles and abstracts of each were reviewed by at least two panel members for relevance, resulting in 463 articles, each of which was reviewed. In the end 79 relevant studies were identified, and these were reviewed and rated by two members using the AAN criteria for the classification of therapeutic articles. Recommendations were linked to the strength of evidence. If the two reviewers disagreed on a study, a third member evaluated it.

WHAT IS THE MOST SIGNIFICANT FINDING IN TERMS OF TREATMENT?

Pregabalin was the only drug with Level A evidence, based on supportive studies that met all of the criteria for thorough methodology and analysis showing that it can reduce pain in PDN and improve quality of life. But doctors should determine if it is appropriate on a case-by-case basis.

There are a lot of options for patient care. Quite a few of the studies had good Level B data, especially antiepileptics and antidepressants. We found a wide variety of agents with a good evidence base, but it all depends on how each patient responds.

WHAT ARE THE OTHER TREATMENT OPTIONS, AND HOW DID THEY RANK IN TERMS OF POTENTIAL EFFECTIVENESS AND SIDE EFFECTS?

Level B evidence supports the use of gabapentin and sodium valproate, antidepressants such as venlafaxine, duloxetine and amitriptyline, and painkillers such as opioids and capsaicin, although each can cause side effects.

The difference between Level A and Level B status reflects the quality of available studies, based on their criteria and methodology, whether they were multicenter studies using placebo, follow-up, and other issues, with Class I studies being the best. We did not rank the effectiveness of any of the agents, but none of the Level B agents fared any better than another.

In general, efficacy data on each of them were very similar, and physicians could start with any of them. Using opioids, however, can be quite difficult because patient tolerance increases the longer they use them, requiring greater dosages to achieve relief. Also, opioids cause constipation, which is also very common in diabetic patients, so their use can exacerbate the problem, and I tend to avoid them.

There have not been enough one-to-one studies, so we cannot really rank their comparative effectiveness — but it tends to be relatively poor. If patients are not comfortable with pregabalin, we recommend trying the Level B options, but it depends on the individual patient's response.

IN THE RESEARCH, HOW MUCH RELIEF CAN PATIENTS EXPECT FOR TREATMENT?

It depends on the patient. In general, none of the medications results in really good relief, but it can be in the 30 percent to 50 percent range. That means if a patient says the pain is six on a scale of ten, treatment, at best, may reduce the pain to a three.

WHAT ARE THE POTENTIAL SIDE EFFECTS OF PREGABALIN?

Fluid retention and weight gain are the most common problems, but patients can suffer peripheral edema as well. More than 10 percent experience drowsiness or dizziness, while 1 percent to 10 percent have visual disturbances, ataxia, speech problems, tremor, lethargy, memory problems, and constipation.

Less common are reports of depression, confusion, agitation, hallucinations, and tachycardia.

A 2009 AAN GUIDELINE FOUND TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) OFFERED NO BENEFIT FOR THESE PATIENTS, BUT THE NEW GUIDELINE DID. WHY THE CHANGE?

The 2009 AAN guideline gave a Level B recommendation for the use of TENS in painful diabetic neuropathy, similar to our guideline. The 2009 guideline failed to find evidence for the use of TENS in chronic low back pain, a different condition than painful diabetic neuropathy.

ARE THERE DATA THAT ANY OF THE OTHER NONPHARMACOLOGIC OPTIONS ARE EFFECTIVE?

We found no evidence that any of these others, such as magnetic shoe inserts, low-intensity laser treatment, Reiki massage, exercise, or acupuncture, had any evidence for efficacy in treating patients.

IS THERE ANY EVIDENCE THAT LONG-TERM TREATMENT WITH PREGABALIN OR ANY OF THE OTHER THERAPIES BECOME LESS EFFECTIVE OVER TIME?

We are unable to answer that question at this time because all of these studies tend to be short-term trials. We know that there is escalation in opioid patients due to increased tolerance, but this is not confirmed with any if the others.

WHAT TYPES OF NEW RESEARCH WOULD BE MOST HELPFUL?

It would help if we had standardized measures of pain, and longer studies that include quality of life and physician function evaluations. PDN needs to be recognized as being a large and common problem, not only in the US, but also throughout the world.

Developing official AAN guidelines will help by giving physicians an evidence-based framework within which to work.

One study showed that while 16 percent of patients suffer chronic neuropathic pain, 12 percent said they had never told their physician, and 39 percent had never been treated for pain.

WHAT DID THE PANEL CONCLUDE ABOUT LONG-TERM RESEARCH NEEDS?

As I said previously, a formal process for rating pain scales is needed for use in all clinical trials, and trials should be expanded to include effects on quality of life and physical function when evaluating the efficacy of new interventions. Further, these measures should be standardized. Future trials should also include head-to-head comparisons of different medications and combinations, and because PDN is chronic, longer trials are needed. Also, standardized metrics for measuring side effects to qualify the effects of interventions need to be developed, and cost-effectiveness studies of different treatments should be performed.

Finally, the actual mechanism of action of electrical stimulation remains unknown, and a better understanding of its role, application, and other aspects of its use should be studied.

Editor's Note: A Recommendation of Caution on the New Guidelines

Neurology Today Associate Editor Robert Holloway, MD: The new guideline on the treatment of painful diabetic neuropathy provides a Level A recommendation for pregabalin and Level B recommendations for 11 drugs, including gabapentin, duloxetine, venlafaxine, amitriptyline, sodium valproate, opiates, and dextromethorphan, among others. Based on the mapping of the evidence available to the recommendation, pregabalin is afforded a “should be offered” treatment recommendation (Level A), while the others received a “should be considered” (Level B).

I believe that the Level A recommendation for pregabalin compared to the Level B recommendations for the others may reflect more about the guideline development process than actual efficacy and safety differences across the treatments.

The guideline development process uses explicit rules to map recommendations from the quantity and quality of evidence available See Levels of Evidence Table. Based on evidence criteria used by the AAN, a Level A recommendation results when there are at least two or more consistent Class I studies. Pregabalin had 3 Class I and 1 Class II studies compared to at least one Class I study or two consistent Class II studies for a Level B recommendation; duloxetine and amitriptyline had 1 Class I and 2 Class II studies; gabapentin and venlafaxine had 1 Class I and 1 Class II studies. Is the weight of one additional Class I study sufficient to change a recommendation from “could” to “should”? This question is important given the use of the pre-specified criteria for distinguishing Class I and II studies. For example, a large randomized clinical trial with 79 percent of the participants completing the study would be considered a Class II study, whereas the exact same trial with a completion rate of 80 percent becomes a Class I study.

Are we demanding too much from the evidence? The heterogeneity and the many nuances involving chronic pain clinical trials make study to study comparisons difficult. In fact, the authors point out that the placebo effect varied from 0 percent to 50 percent for pain reduction across the studies despite generally small to moderate incremental reductions in pain and other patient-reported outcomes for most of the therapies evaluated.

Moreover, there was limited attention to safety and tolerability in formulating these guidelines. To recommend, for example, amitriptyline, dextromethorphan, duloxetine, and sodium valproate on an equal footing is discordant with existing treatment guidelines for neuropathic pain and may place patients at an increased risk of serious adverse events.

Therefore, I recommend that the “should be offered” versus “should be considered” distinction be de-emphasized when looking across the attributes of these agents. It is important for practitioners using this guideline to appreciate that distinctions between Level A and B evidence are but one component of decision making regarding appropriate initial therapy for neuropathic pain in diabetic peripheral neuropathy. Other important factors include safety, cost, patient preference, comorbidities, and physician comfort.


http://journals.lww.com/neurotodayonline/Fulltext/2011/05050/New_Evidence_Based_Guidelines_for_Painful_Diabetic.1.aspx

Wednesday, June 21, 2017

New Drugs To Target Melatonin Receptors For Neuropathic Pain


Today's post from medicalxpress.com (see link below) looks at the potential melatonin has for relieving neuropathic pain. You've probably heard of melatonin in relation to sleep problems but previous research has shown that over-the-counter melatonin has no effect on nerve pain problems. Now scientists have found that UCM924, a melatonin MT2 receptor drug, relieves chronic pain in animal models because it is directed at the right pain receptors in the brain. In this way, it can turn off the neurons responsible for sending pain signals. An interesting development that may bear fruit in the future.

Study shows potential new therapy for neuropathic pain
Provided by McGill University February 18, 2015

An international study led by scientists at McGill University reports, for the first time, that drugs that selectively target the melatonin MT2 receptor represent a novel class of analgesic drugs that could be used to treat patients with neuropathic pain.

Neuropathic pain is a disorder characterized by severe pain that sometimes develops following nerve damage resulting from conditions such as shingles, injury, amputation, autoimmune inflammation and cancer. It is a permanent pain that persists for months or years.

An estimated 7% to 8% of adults worldwide suffer from neuropathic pain, with 5% of cases considered severe. The problem has significant economic implications, including reduced productivity and substantial health care costs.

Melatonin, a neurohormone present in mammals, acts on the brain by activating two receptors called "MT1" and "MT2" that are responsible for regulating several functions including sleep, depression, anxiety and circadian rhythms.

Now, a team led by Dr. Gabriella Gobbi, Associate Professor in the Department of Psychiatry of McGill's Faculty of Medicine, has demonstrated that UCM924, a melatonin MT2 receptor drug, relieves chronic pain in animal models; the team has also identified the drug's mechanism of action in the brain. UCM924, by activating the MT2 receptors in the periaqueductal grey (a brain area controlling pain), is able to switch off the neurons that trigger pain and switch on the ones that turn off pain. The findings are reported in the February issue of the journal PAIN.

"There are very limited treatments available for neuropathic pain, and a lot of patients use opioids," says Dr. Gobbi, who is also a researcher at the Research Institute of the McGill University Health Centre (RI-MUHC). "In the long term, these can lead to addiction and severe side effects, including dependence and tolerance, opioid-induced hyperalgesia (the pain becomes even worse), and risk of death. For these reasons, identifying novel analgesics is of keen interest in the medical field today."

Previous studies have shown that over-the-counter melatonin has very limited effect. Dr. Gobbi and her team demonstrated that this is because exogenous melatonin activates both MT1 and MT2 receptors, which have conflicting and opposite effects.

In the course of their work to investigate the efficacy of MT2 receptor drugs for insomnia, the researchers discovered that UCM924 also soothes neuropathic pain at lower doses. This suggests that these drugs could offer relief both to people who suffer from pain during the day, using low doses, and from insomnia at night, using higher doses. At least 50-70% of patients with neuropathic pain conditions complain of significant sleep disturbance, and this new study unveils how the mechanisms of pain and sleep are closely related.

The research team is now looking for partners interested in pursuing clinical development and eventual commercialization of these novel drugs.

Explore further: Combining epilepsy drug, morphine can result in less pain, lower opioid doses

More information: "Selective melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways" Martha Lopez-Canul, Enza Palazzo, Sergio Dominguez-Lopez, Livio Luongo, Baptiste Lacoste, Stefano Comai, Debora Angeloni, Franco Fraschini, Serena Boccella, Gilberto Spadoni, Annalida Bedini, Giorgio Tarzia, Sabatino Maione, Vinicio Granados-Soto, Gabriella Gobbi., Pain. 2015 Feb; 156(2):305-17. DOI: 10.1097/01.j.pain.0000460311.71572.5f.

Journal reference: Pain

http://medicalxpress.com/news/2015-02-potential-therapy-neuropathic-pain.html

Tuesday, June 20, 2017

Anti Muscarinics New Wonder Drugs For Neuropathy Or The Latest In A Long Line Of Nice Tries!


Today's post from painnewsnetwork.org (see link below) is one of a series of current articles all across the net about a potentially very effective new treatment for neuropathy. The difference between this one and the rest is that you can understand it, so kudos to the author for having 'translated' complex science into a language we can all understand. The article looks at a new development and study (still, unfortunately, at the rodent testing stage) aimed at blocking sensory nerves with medication, in order to cut out pain signals to the brain. By using the drug Pirenzepine (currently used to treat various conditions including Parkinson's) it is said that nerve growth and repair can be stimulated and that in itself is something new! If this drug is also effective on humans, it could provide a major breakthrough in the treatment of neuropathy. So many articles about this family of drugs are popping up that you get the feeling that serious people are seriously excited about it. Let's hope it all works out as it's meant to but scientists will have to accept that neuropathy patients have been here before and skepticism is more the order of the day than optimism. Nevertheless, it sounds very promising indeed. Remember that name...Pirenzepine.

Medication Could Reverse Peripheral Neuropathy  
By Pat Anson, Editor January 19, 2017

Blocking a sensory nerve signal with medication could prevent or even reverse symptoms of peripheral neuropathy, according to new research published in the Journal of Clinical Investigation.

About 20 million Americans suffer from peripheral neuropathy, which often causes a painful stinging or burning sensation in the hands or feet.


"Peripheral neuropathy is a major and largely untreated cause of human suffering," said lead author Nigel Calcutt, PhD, a professor of pathology at the University of California San Diego School of Medicine. "It has huge associated health care costs."

In studies on diabetic laboratory rats, Calcutt and his colleagues identified a molecular signaling pathway that, when blocked with the drug pirenzepine, promotes sensory neuron growth and prevents or reverses the nerve damage caused by peripheral neuropathy.

The discovery suggests that pirenzepine and other anti-muscarinic drugs – a class of nerve medication that is already used to treat Parkinson’s disease, motion sickness, irritable bowel syndrome and other conditions – could be used as a new treatment for peripheral neuropathy.

"This is encouraging because the safety profile of anti-muscarinic drugs is well-characterized, with more than 20 years of clinical application for a variety of indications in Europe," said senior study author Paul Fernyhough, PhD, a professor in the departments of pharmacology and therapeutics and physiology at the University of Manitoba in Canada. "The novel therapeutic application of anti-muscarinic antagonists suggested by our studies could potentially translate relatively rapidly to clinical use."

The first symptoms of peripheral neuropathy are usually a tingling or numbing sensation in the toes, feet, and hands caused by small fiber nerve damage. The symptoms progress, spread and become more painful, dramatically affecting quality of life.

Researchers say treating the disease in its early stages is key.

“Since small fiber degeneration develops early in the human disease and can be reliably quantified using a variety of minimal or noninvasive techniques that can be applied iteratively, future clinical trials of anti-muscarinic drugs might feasibly focus on reversal of these early indices of neuropathy,” they said.

“Further, as anti-muscarinic drugs were effective in augmenting collateral (nerve) sprouting in our in vitro assay, this new therapeutic approach may be most effective during the early stages of a dying-back neuropathy prior to overt and/or complete fiber loss.”

Nearly 26 million people in the United States have diabetes and about half have some form of neuropathy, according to the American Diabetes Association. Small fiber neuropathy can also be caused by lupus, HIV, Lyme disease, celiac disease or chemotherapy.

https://www.painnewsnetwork.org/stories/2017/1/19/medication-could-reverse-peripheral-neuropathy

Sunday, June 18, 2017

Statin Drugs Neuropathy And Driving


Today's post from elderlydriver.org (see link below) looks at the effects of statin drugs on driving ability for the elderly. Statin drugs are generally prescribed to lower cholesterol levels and thus reduce the risk of cardiovascular disease. the problem is that these drugs can bring on neuropathy and nerve damage, or if you already have it, make it a lot worse. If you already have neuropathy and your cholesterol levels are too high, it's important that you discuss the consequences with your doctor. Needless to say, neuropathy in the feet is not good if you're relying on touch and 'feel' while driving. Add this to muscle weakness and lack of response due to statins and you may end up in a dangerous situation without being aware of the reasons behind your sudden loss of control. Taking advice is certainly logical.


Adverse Side Effects of Statin Drugs Can Affect the Way You Drive
By Admin: Feb 14th 2013

Muscle Pain and Weakness

As discussed in part 1 of this article, notwithstanding their ability to effectively lower cholesterol levels, there are several adverse side effects of stain drugs of which you, the elderly driver, should be aware. In the previous article we touched on those side effects that can keep you temporarily or even permanently from driving. In this article, we want to emphasize the five adverse side effects of stain drugs that can affect the way you drive.

Numerous users of statins have reported muscle pain and weakness, probably because an essential nutrient, Co-Q10, that supports muscle function, has been depleted. Contrary to the 2% to 3% the industry claims is the case, one well-known researcher found that 98% of patients taking Lipitor, the leading statin on the market, complain of such pain and weakness. You can well imagine then how pain and, especially weakness are adverse side effects of statin drugs that can directly impact the elderly motorist’s driving performance.

Neuropathy

Another, among the most common adverse side effects of statin drugs, is peripheral neuropathy. This is characterized by weakness, tingling and pain in the hands and feet, as well as difficulty walking. If a patient is a long-time user, say 2+ years, he or she is anywhere from four to fourteen times more at risk of such symptoms and often, regrettably, with irreversible damage. Researchers at the Weston Foundation, Sally Fallon and Mary G. Enig, PhD, have noted that, “people who take large doses for a long time may be left with permanent nerve damage, even after they stop taking the drug.” So they have speculated on “whether widespread statin-induced neuropathy makes our elderly drivers (and even not-so-elderly drivers) more accident prone?”

Dizziness

Likely due to their ability to lower blood pressure, dizziness is another among theadverse side effects of statin drugs, often reported by users. The elderly may be particularly sensitive to drops in blood pressure and, thus, susceptible to serious risks while driving.

Cognitive Impairment

Statin drugs have been known to cause fading of speech and memory, making it difficult to carry on a conversation. One university study demonstrated that patients taking statins for half a year had considerably more difficulty “solving complex mazes, psychomotor skills and memory tests” than patients on a placebo. Well known researcher, Dr. Golomb, has determined that 15% percent of patients on statin drugs suffer from side effects involving cognition.

Among the most dramatic adverse side effects of statin drugs are reported incidences of global transient amnesia (GTA), i.e., total memory loss for a period of time. Former astronaut, Duane Graveline, in his book Lipitor: Thief of Memory, reports on this condition from personal first hand experience during two episodes of GTA. Sufferers of GTA report disconcerting, often mystifying events where they experience total memory loss finding themselves in some location, not knowing how they got there, why they were there, who they were or who were their relative, where they lived and unable to find their car. Just as suddenly this transient state would disappear and all cognition would be restored, as usual. Clearly this a risk to all when so many are taking statins.

See ABC Report on Statins and Global Transient Amnesia


Depression

Several studies have noted a correlation of low cholesterol with depression, suicide and violence. A huge Finnish study of 29,00 men correlated low cholesterol levels with greater risk of depression and suicide. Women with low cholesterol were two times more likely to suffer from depression and anxiety, another study found. In previous studies on men, Dr. Suarez (an advocate of statins) found that men who lower their cholesterol levels with medication have increased rates of suicide and violent death, leading the researchers to theorize “that low cholesterol levels were causing mood disturbances.”

The following video from Dr. Joseph Mercola, a leading advocate of natural medicine reviews much of what has been cited in this article and offers advice on what to do with the many adverse side effects of statin drugs.

Dr.Mercola video
If you are an elderly driver and you are on statins, do yourself a favour and do some “homework” to insure that you are using statins for the right reason. The adverse side effects of statin drugs are real and numerous. If you are manifesting any of the side effects mentioned in this article, get to your physician as soon as possible. Don’t wait until it is too late and you can’t drive any longer. Don’t wait until your driving performance is adversely affected.

http://www.elderlydriver.org/blog/adverse-side-effects-of-statin-drugs-and-the-elderly-driver-2


Tuesday, June 13, 2017

Anti Epilepsy Drugs Control Nerve Pain


Today's post from mayoclinic.org (see link below) is very useful for those already taking anti-epilepsy drugs for their neuropathy, or those for whom that may become an option in the future. Many people are confused and more than a little alarmed as to why they're being given anti-seizure drugs for nerve damage. This article explains the reasoning behind prescribing those drugs for neuropathy. As you look through the list below, you'll probably recognise some of the drugs from your other research into the disease. The fact is, nobody is totally certain why anti-seizure drugs work for nerve pain (in some cases, not all and side-effects are an issue!) but it's clear that they block pain signals sufficiently to be effective. Worth a read.
 


Anti-seizure medications: Relief from nerve pain By Mayo Clinic Staff

 Anti-seizure drugs often are used to help control the type of pain caused by damaged nerves.

Anti-seizure medications were originally designed to treat people with epilepsy. But the nerve-calming qualities of some of these medications can also help quiet the burning, stabbing or shooting pain often caused by nerve damage. 


Why does it hurt?

Nerves can be damaged by many things, including injury, surgery, disease or exposure to toxins. The damaged nerves are activated inappropriately and send pain signals that don't serve a useful purpose. This type of pain can be debilitating and difficult to control.

Nerve damage
(neuropathy) can be caused by many conditions, including:
Diabetes. High blood sugar levels, common in diabetes, can damage nerves throughout your body. The first symptom generally is numbness and pain in your hands and feet (diabetic neuropathy).
Shingles. Anyone who has had chickenpox is at risk of shingles, a rash of blisters that can be painful or itchy. A condition called postherpetic neuralgia occurs if shingles pain persists after the rash disappears.
Because the risk of shingles increases with age, everyone age 50 and older should receive the varicella-zoster virus vaccine (Zostavax), which can help prevent this painful condition.

Chemotherapy.
Some chemotherapy drugs can damage nerves, causing pain and numbness that generally begin in the tips of your toes and fingers (neuropathy).
Herniated disk. Nerve damage can occur if a herniated disk in your spine squeezes a nerve passing through your vertebrae too tightly.
Fibromyalgia. Fibromyalgia is a chronic condition that causes pain and tenderness throughout your body. 


How do anti-seizure drugs help?

The exact mechanism of action isn't fully understood, but anti-seizure medications appear to interfere with the overactive transmission of pain signals sent from damaged nerves.

Some anti-seizure drugs work particularly well for certain conditions. Carbamazepine (Carbatrol, Tegretol) is widely prescribed for trigeminal neuralgia, a condition that causes searing facial pain that feels like an electric shock.

It's important to note that the Food and Drug Administration has issued a warning that all anti-seizure medications are associated with a slightly increased risk of suicidal thoughts or actions. Talk to a doctor or counselor promptly if you feel depressed or suicidal.
 
Newer anti-seizure drugs may have fewer side effects

More recent research supports the use of the anticonvulsants gabapentin (Neurontin) or pregabalin (Lyrica) to help relieve pain caused by damaged nerves.

Both gabapentin and pregabalin are particularly effective in the treatment of postherpetic neuralgia, diabetic neuropathy and pain caused by a spinal cord injury. Pregabalin also may be used to treat fibromyalgia.

Because these drugs have few side effects and are usually well tolerated, they are often the first medications to try for neuropathic pain. You may experience side effects, such as drowsiness, dizziness, confusion or swelling in the feet and legs. These side effects are limited by starting with a low dosage and slowly increasing it.

Medications from other drug classes with distinct mechanisms of pain relief (such as antidepressants) may be used in combination with anti-seizure class medications if anti-seizure medications fail to control your pain. 


Side effects limit use of older anticonvulsants

Anti-seizure drugs have been used to treat nerve pain for many years, but their use was limited by the severity of side effects they produce.

Older anti-seizure drugs include:
Carbamazepine (Carbatrol, Tegretol)
Oxcarbazepine (Trileptal)
Phenytoin (Dilantin)
Valproic acid (Depakene)

Side effects may include:
Liver damage
Nausea
Vomiting
Double vision
Loss of coordination
Drowsiness
Headache

If you take an older anticonvulsant, you generally need regular follow-up visits so that your doctor can monitor for side effects. These older drugs often have more side effects than do the newer anticonvulsants, and the evidence supporting use of the older anticonvulsants for neuropathic pain is sparse at times. As a result, older drugs may be recommended only when the newer medications prove ineffective. 


Research continues

As scientists learn more about the way anti-seizure drugs work, this information will be useful in determining which drugs may work best for different types of nerve pain. Pain caused by nerve damage can be disabling, but anti-seizure drugs sometimes provide relief.

http://www.mayoclinic.org/diseases-conditions/peripheral-neuropathy/in-depth/pain-medications/art-20045004